3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer

• Published in: Radiotherapy and oncology 2004-04, Vol.71 (1), p.35-41
• Main Authors: Martin, Thomas, Röddiger, Sandra, Kurek, Ralf, Dannenberg, Thomas, Eckart, Oliver, Kolotas, Christos, Heyd, Reinhard, Rogge, Bernd, Baltas, Dimos, Tunn, Ulf, Zamboglou, Nikolaos
• Format: Article
• Language: English
• Subjects: 3D external beam radiation; Aged; Aged, 80 and over; Androgen Antagonists - therapeutic use; Androgen deprivation; Antineoplastic Agents, Hormonal - therapeutic use; Brachytherapy; Combined Modality Therapy; Gonadotropin-Releasing Hormone - therapeutic use; HDR brachytherapy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prostate cancer; Prostatic Neoplasms - radiotherapy; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Treatment Outcome
• ISSN: 0167-8140; 1879-0887
• DOI: 10.1016/j.radonc.2003.10.004

Purpose: To evaluate treatment outcome of 3D conformal high dose rate (HDR) brachytherapy and external beam irradiation (EBRT) combined with temporary androgen deprivation for patients with localized prostate cancer. Patients and methods: Between January 1997 and September 1999 we treated 102 patients with stage T1–3 N0 M0 prostate cancer. Stage T1–2 was found in 71, T3 in 31 patients. Median pretreatment PSA level was 15.3 ng/ml. After ultrasound-guided transrectal implantation of four afterloading needles, CT based 3D brachytherapy planning was performed. All patients received four HDR implants using a reference dose per implant of 5 or 7 Gy. Time between each implant was 14 days. After brachytherapy EBRT followed up to 39.6 or 45.0 Gy. All patients received temporary androgen deprivation, starting 2–19 months before brachytherapy, ending 3 months after EBRT. Results: Median follow-up was 2.6 years (range 2.0–4.1 years). Actuarial biochemical control rate was 87% at 2 years and 82% at 3 years. In 14 patients we noted biochemical failure, in five patients clinical failure. Overall survival was 90%, disease specific survival 98.0% at 3 years. Acute grade 3 toxicity occurred in 4%, late grade 3 toxicity in 5%. One patient developed a prostatourethral-rectal fistula as late grade 4 toxicity. The conformal quality of 300 HDR implants was analyzed using dose volume histograms. Conclusions: 3D conformal HDR brachytherapy and EBRT combined with temporary androgen deprivation is an effective treatment modality for prostate cancer with minimal associated toxicity and encouraging biochemical control rates after a median follow-up of 2.6 years.